Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$135,000.00

5T4-CAR-NKT cell therapy for pediatric rhabdomyosarcoma

FY 2017-18

Summary
Pediatric rhabdomysarcoma is a deadly disease affecting children and adolescents. While current radiation and chemotherapy can provide effective long-term tumour control in ~70% of patients, they are very toxic. Patients commonly suffer from decreased cognitive capabilities, fertility problems and even susceptibility to other types of cancers later in life. And for ~30% of RMS patients, there are no good treatment options. Therefore, there is urgent need to reduce the toxicity of RMS therapies and improve their effectiveness. The Mahoney lab is dedicated to discovering and developing new ways to treat RMS by harnessing the power of the immune system to attack and kill RMS cells. One promising approach is by engineering immune cells to express a synthetic protein called a "chimeric antigen receptor", or CAR. Immune cells engineered with CARs are able to better recognize and kill cancer cells. For my postdoctoral project, I propose to test the feasibility of using CAR technology to focus the immune system toward RMS. Additionally, I propose to evaluate whether two other therapies known to generate immune responses toward cancer will enhance the ability of CAR-engineered immune cells to destroy RMS tumours. If successfully, my research aims to provide a strong justification for testing CAR technology in human patients with RMS.
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
376140
Name
Gebremeskel Simon Y
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
5T4-CAR-NKT cell therapy for pediatric rhabdomyosarcoma
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer; Car T Cells; Immunotherapy; Oncolytic Virus Therapy; Rhabdomyosarcoma; Tumor Antigen
Abstract
Pediatric rhabdomysarcoma is a deadly disease affecting children and adolescents. While current radiation and chemotherapy can provide effective long-term tumour control in ~70% of patients, they are very toxic. Patients commonly suffer from decreased cognitive capabilities, fertility problems and even susceptibility to other types of cancers later in life. And for ~30% of RMS patients, there are no good treatment options. Therefore, there is urgent need to reduce the toxicity of RMS therapies and improve their effectiveness. The Mahoney lab is dedicated to discovering and developing new ways to treat RMS by harnessing the power of the immune system to attack and kill RMS cells. One promising approach is by engineering immune cells to express a synthetic protein called a "chimeric antigen receptor", or CAR. Immune cells engineered with CARs are able to better recognize and kill cancer cells. For my postdoctoral project, I propose to test the feasibility of using CAR technology to focus the immune system toward RMS. Additionally, I propose to evaluate whether two other therapies known to generate immune responses toward cancer will enhance the ability of CAR-engineered immune cells to destroy RMS tumours. If successfully, my research aims to provide a strong justification for testing CAR technology in human patients with RMS.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gebremeskel, Simon Y
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
University of Calgary - $135,000 Grant (2017-18) | Canada Spends